ReviewBiochimica et biophysica acta
HMGNs, DNA repair and cancer.
Review in Biochimica et biophysica acta. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 55 citations in OpenAlex.
- Insights into Tardigrade Damage-Suppression Protein, Dsup.Biomolecules · 2026Review
- High mobility group protein N2 inhibits the progression of hepatocellular carcinoma and the related molecular mechanisms.Cytotechnology · 2025Article
- Early monitoring values of oncogenic signalling molecules for hepatocellular carcinoma.World journal of gastrointestinal oncology · 2024Article
- HMGN1 loss sensitizes lung cancer cells to chemotherapy.Scientific reports · 2024Article
- The role of high mobility group proteins in cellular senescence mechanisms.Frontiers in aging · 2024Review
- Next-Generation Sequencing in the Assessment of the Transcriptomic Landscape of DNA Damage Repair Genes in Abdominal Aortic Aneurysm, Chronic Venous Disease and Lower Extremity Artery Disease.International journal of molecular sciences · 2022Article
- Investigation of the effects of overexpression of jumping translocation breakpoint (JTB) protein in MCF7 cells for potential use as a biomarker in breast cancer.American journal of cancer research · 2022Article
- Telomeres reforged with non-telomeric sequences in mouse embryonic stem cells.Nature communications · 2021Article
- Human HMGN1 and HMGN2 are not required for transcription-coupled DNA repair.Scientific reports · 2020Article
- Biological Functions of HMGN Chromosomal Proteins.International journal of molecular sciences · 2020Review
- Regulation of epigenetic state by non-histone chromatin proteins and transcription factors: Implications in disease.Journal of biosciences · 2020Review
- The interactome and proteomic responses of ALKBH7 in cell lines by in-depth proteomics analysis.Proteome science · 2019Article
- [Clinical application of high mobility group box nuclear protein 1 subcomponent in the progression of liver cancer].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2018Article
- Abnormal expression ofWorld journal of gastroenterology · 2018Article
- Increased expression of high-mobility group nucleosomal-binding domain 2 protein in various tumor cell lines.Oncology letters · 2018Article
- High mobility group box 3 as an emerging biomarker in diagnosis and prognosis of hepatocellular carcinoma.Cancer management and research · 2018Article
- Knockdown of HMGN5 increases the chemosensitivity of human urothelial bladder cancer cells to cisplatin by targeting PI3K/Akt signaling.Oncology letters · 2017Article
- Elevated HMGN4 expression potentiates thyroid tumorigenesis.Carcinogenesis · 2017Article
- Combined clinical and genomic signatures for the prognosis of early stage non-small cell lung cancer based on gene copy number alterations.BMC genomics · 2015Article
- Knockdown of HMGN5 suppresses the viability and invasion of human urothelial bladder cancer 5637 cells in vitro and in vivo.Medical oncology (Northwood, London, England) · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
DNA lesions threaten the integrity of the genome and are a major factor in cancer formation and progression. Eukaryotic DNA is organized in nucleosome-based higher order structures, which form the chromatin fiber. In recent years, considerable knowledge has been gained on the importance of chromatin dynamics for the cellular response to DNA damage and for the ability to repair DNA lesions. High Mobility Group N1 (HMGN1) protein is an emerging factor that is important for chromatin alterations in response to DNA damage originated from both ultra violet light (UV) and ionizing irradiation (IR). HMGN1 is a member in the HMGN family of chromatin architectural proteins. HMGNs bind directly to nucleosomes and modulate the structure of the chromatin fiber in a highly dynamic manner. This review focuses mainly on the roles of HMGN1 in the cellular response pathways to different types of DNA lesions and in transcriptional regulation of cancer-related genes. In addition, emerging roles for HMGN5 in cancer progression and for HMGN2 as a potential tool in cancer therapy will be discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.